An Open-Label, Multiple Ascending-Dose, Study to Evaluate the Pharmacokinetic Profile and D2 Occupancy of HP-3070 Patch in Subjects Diagnosed with Schizophrenia

Trial Profile

An Open-Label, Multiple Ascending-Dose, Study to Evaluate the Pharmacokinetic Profile and D2 Occupancy of HP-3070 Patch in Subjects Diagnosed with Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Asenapine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Hisamitsu Pharmaceutical
  • Most Recent Events

    • 18 Nov 2016 Status changed from recruiting to completed.
    • 02 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top